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CObjective: A number of hemophilia A patients who receive clotting
factors may develop antibodies (inhibitors) against clotting factors. The
immune tolerance induction (ITI) method has proved to be a very cost-
effective alternative to bypassing agents. Iran’s national health author-
ity is interested in implementing the ITI method for the management
of hemophilia patients with inhibitors. The objective of this study was
to calculate the breakeven point between costs attributed to the ITI
method and the use of bypassing agents for the management of high-
responder hemophilia patients with inhibitors. Methods: This study
ssessed costs attributed to the implementation of ITI for the manage-
ent of Iranian hemophilia patients with costs of high-titer and high-
esponding inhibitors from the perspective of the national health sys-
em. The main objective was to find the breakeven point for the ITI
ethod in comparison with the use of bypassing medicine, recombi-
ant factor VIIa (Novoseven).Results: Based on the sensitivity analysis
erformed, the breakeven point mainly depends on costs of factor VIII,
ovoseven, and the success rate of the ITI intervention. According to O
e no
rans
al So
doi:10.1016/j.vhri.2012.03.014his analysis, the breakeven point of ITI and Novoseven methods varies
etween 16 and 34 months posttreatment. The optimized point is
bout 17 months posttreatment. Conclusions: Iran’s national health
ystem spends more than 24 million euros for providing bypassing
gents to about 124 hemophilia patients with inhibitors. Because of
imited resources available in Iran’s health sector, this is a huge bur-
en. Results of this study show that the implementation of the ITI
ethod for the management of Iranian hemophilia patients with in-
ibitors is a cost-saving method and Iran’s health system will recover
ll the expenditure related to the implementation of ITI in less than 2
ears and will make a considerable saving along with providing stan-
ard care for these patients.
eywords: cost assessment, hemophilia patients, immune tolerance
nduction, Iran.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Hemophilia is a rare inherited blood disorder that normally affects
males. About 1 in 10,000 newborns may have this congenital dis-
order. These patients lack sufficient clotting factors VIII, IX, or, in
rare cases, other clotting factors. Efficient management of hemo-
philia patients and their complications require appropriate ad-
ministration of clotting factors. Otherwise, these patients may
face massive internal and external bleeding. However, some of
these patients may develop antibodies against clotting factors
during the course of treatment. This is mainly due to an immune
response against clotting factor concentrates. This will ultimately
produce neutralizing antibodies, which are named “inhibitors.”
Inhibitors could occur in 15% to 35% of patients with severe hemo-
philia A. In addition to immune system response, factors such as
severity of the disease, age, type of mutation, genetics, and previ-
ous exposure to clotting factors may play roles in developing in-
hibitors. Inhibitor titer is measured by Bethesda units (BU). Pa-
tients are categorized to low titer (5 BU) and high titer (5 BU).
Although high doses of factor VIII (FVIII) concentrate could mange
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Published by Elsevier Inc.patients with low titer of inhibitors, high-titer patients require
other types of medicines named “bypassing” agents. Otherwise,
their bleeding cannot be controlled and will lead to severe compli-
cations or death [1,2].
Patients with inhibitors may face serious bleeding episodes
that of course do not respond to regular clotting factor replace-
ment therapy. Bleeding into muscles and joints may cause perma-
nent joint damage. Currently, there are two main approaches for
managing hemophilia patients with inhibitors. These patients
could be treated by using bypassing agents such as recombinant
FVIIa and activated prothrombin complex concentrate. These
medicines stop the bleeding by providing activated or partially
activated forms of FVII and/or factor X. However, these medicines
are very expensive and for many patients, especially those living
in developing countries, unaffordable. Data reported show that
the use of bypassing agents for the management of these patients
may even increase costs of treatment up to 12 times [3,4].
The second approach for managing hemophilia patients with
inhibitors is immune tolerance induction (ITI). For three decades
ITI has been used with promising efficiency for the management
of hemophilia patients with inhibitors. With recent scientific con-
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patients with inhibitors [5]. ITI could eliminate FVIII inhibitors and
restore normal clinical response to FVIII in these patients. Recent
published reports indicate the efficiency and cost-effectiveness of
the ITI intervention in patients with inhibitors [4–7]. These reports
clearly explain the benefits of this method, especially in young
children who have recently developed inhibitors against FVIII.
Iran is a country with a population of more than 74 million and
has a very well-defined and comprehensive national program for
the management of hemophilia. According to a global survey by
World Federation of Hemophilia, Iran has the second highest
number of hemophilia cases in the Eastern Mediterranean region.
According to Iran’s Ministry of Health (MOH) statistics, currently
there are about 7300 patients with congenital bleeding disorders
registered in Iran, with 4100 of them having hemophilia A [8]. Two
separate studies have reported that about 3.8% to 4% of Iranian
hemophilia patients may develop high-titer antibodies against
FVIII [9,10]. According to Iran’s MOH, currently there are about 124
registered hemophilia A patients with inhibitors in Iran. Costs of
hamophilia care in Iran are fully covered by the government of
Iran through payment of direct subsidy for the medicines and
costs of other cares used by these patients. The per-capita con-
sumption of FVIII in Iran is reported to be 1.8 IU [11]. Despite the
presence of such a comprehensive national program, however, it
seems that the Iranian society has been faced by some social con-
sequences that have arisen from this program [12].
Despite the low number of hemophilia patients with inhibitors
in Iran, the cost attributed to the management of bleeding epi-
sodes through the administration of bypassing agents is huge. It is
estimated that every year Iran’s national health system spends
more than 24 million euros for the importation of bypassing
agents. However, it seems that because of direct payment of the
government subsidies to the importing pharmaceutical compa-
nies, which results in a very low price of bypassing agents in Iran’s
market and very low surveillance regarding the administration
and use of these medicines in Iran’s market, some parts of these
medicines are either wasted or used in other clinical applications
such as hemostatic agents in nonhemophilia patients.
The per-capita expenditure on health in Iran is about US $700
[12]. Therefore, despite the presence of very few number of hemo-
philia patients with inhibitors, costs of treatment of these patients
with bypassing agents place a huge burden on Iran’s health sector.
It is clear that overall high costs of treating patients with inhibitors
are largely attributed to only very small number of patients who
use large amounts of bypassing agents. Recently, Iran’s MOH de-
cided to establish a trial on the implementation of ITI for the man-
agement of hemophilia patients with inhibitors. Although one of
the objectives of this initiative was to evaluate the clinical efficacy
of ITI in Iranian hemophilia patients with inhibitors, Iran’s MOH
was also interested in estimating the costs of this treatment com-
pared with the costs of current traditional use of bypassing agents.
This study was designed to compare costs attributed to the imple-
mentation of ITI for the management of high-responder Iranian
hemophilia patients with costs of administration of on-demand
therapy using bypassing agents.
Methods
The objective of this study was to calculate costs attributed to the
implementation of ITI for the management of Iranian hemophilia
patients with high-titer and high-responding inhibitors from the
perspective of the national health system. The main objective was
to find the “breakeven” point for the ITI method in comparison
with the use of bypassing agents. Recombinant factor VIIa (Novos-
even) as the most used bypassing medicine for the management of
these patients in Iran was used for the purpose of cost comparison
with the ITI method. To measure the costs of the ITI method inIranian hemophilia patients with inhibitors, Iran’s MOH decided
to set up a trial including 10 patients in each arm of the study. Peak
historical titer less than 200 BU and pre-ITI titer less than 10 BU
were considered as the inclusion criteria for including good risk
patients in the ITI arm [5]. Patients should also have an interval of
fewer than 5 years between inhibitor diagnosis and the start of ITI.
National consensus of expert panel was used as treatment proto-
col for both arms of the study. The ITI regimen in this model was
defined as 100 IU/kg/d of FVIII. Bleeding events of the patients
were divided into three categories as follows [5,7]:
1. Mild events, which could be treated with a standard dose of
medicines at home;
2. Moderate events, which could be managed by the administra-
tion of a double dose of medicines; and
3. Severe events, which need hospitalization for their management.
Presumptions for both groups of this study are summarized in
Tables 1 and 2. Complete response was defined as no detectable
level of inhibitors, in vitro recovery of more than 66%, along with
half-life of FVIII of more than 6 hours. Partial response was defined
as decrease in inhibitor to less than 5 BU, without in vitro recovery,
and half-life improvement, and no response was defined as not
able to reduce inhibitor titer to less than 5 BU after completing the
treatment course [13]. Iran’s MOH was interested in finding out
how long it will take to reach a breakeven point following the
implementation of the ITI intervention. Therefore, to simplify the
calculations, except for medicine costs, we assumed identical
costs for utilized resources in both groups. A simple cost compar-
ison method was used to find out the breakeven point for these
two groups. The breakeven point was defined as the intersection
of costs versus time graphs of these two methods. Costs of medi-
cines for second and third years post treatment were discounted
Table 1 – Presumptions for the ITI arm.
Success rate of ITI 80%
Dose of FVIII 100 IU/kg/d
Mean time to success 12 mo
Dose of Novoseven to control bleeding
events in the first year
Minor events 270 g/kg
Intermediate events 540 g/kg
Major events 5400 g/kg
No. of bleeding events in the first year
(during ITI implementation)
Minor events 1.5
Intermediate events 1
Major events 0.1
No. of bleeding events in second and
third years (for on-demand
therapy with FVIII in patients
managed with the ITI method in
the first year)
Minor events 27
Intermediate events 3
Major events 0.2
Dose of FVIII to control bleeding events
in second and third years
Minor event 40 IU/Kg/d
Intermediate event 80 IU/Kg/d
Major event 100 IU/Kg/d
Price of FVIII in Iran’s market* 3000 rials/IU
Mean estimated patient’s weight of a
6-y-old child
20 kg (with annual
10% increase)
FVIII, factor VIII; ITI, immune tolerance induction.
* Based on the official exchange rate: 1 US $ 12,260 rials.on the basis of a discount rate of 7.5% [14].
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The ITI group
It was assumed that following the receipt of 100 IU/Kg/d of FVIII for
1 year, 80% of patients with inhibitors will respond to the treat-
ment (success rate of 80%) and in following years they will only
need FVIII as on-demand therapy for the management of their
bleeding episodes. However, it was assumed that this group of
patients in the first year of treatment will also need bypassing
agents for the management of their bleeding episodes. The num-
ber of minor, intermediate, and major bleeding events in these pa-
tients will be 1.5, 1, and 0.1 episodes annually, respectively [5,15].
However, these patients will face 27, 3, and 0.2 minor, intermediate,
and major bleeding events after the first year of treatment. Subse-
quently, their bleeding would be treated on demand with FVIII sim-
ilar to that in other hemophilia patients without inhibitors. This pat-
tern will also continue in the third year and in the following years of
their life.
Twenty percent of patients who are assumed not to respond to
ITI even after 1 year of treatment with 100 IU/Kg/d of FVIII still
need Novoseven for the management of their bleeding episodes.
The incidence of minor, intermediate, and major bleeding events
in these patients is estimated similar to that of other on-demand
treated hemophilia patients without inhibitors. The number of
events is considered to be 27, 3, and 0.2 episodes, respectively, in
the next years.
On-demand therapy with bypassing agent (Novoseven) group
This group also consisted of 10 patients. These patients will re-
ceive Novoseven for the management of their bleeding events.
The incidence of minor, intermediate, and major bleeding events
in these patients will be 27, 3, and 0.2 episodes, respectively, sim-
ilar to that in other on-demand treated hemophilia patients with-
out inhibitors. The dose of Novoseven for these patients is sum-
marized in Table 2.
Table 3 – Variables used for sensitivity analysis on the
breakeven point of ITI and Novoseven methods.
Variable Range
ITI success rate 60%–80%
Price* of factor VIII 2000–4000 rials/IU
Price* of
Novoseven
6000–8000 rials/g
ITI, immune tolerance induction.
Table 2 – Presumptions for the bypassing agent group.
Success rate of Novoseven 95%
Dose of Novoseven to control bleeding events
Minor events 270 g/kg
Intermediate events 540 g/kg
Major events 5400 g/kg
No. of bleeding events per year in on-demand
therapy method
Minor events 27
Intermediate events 3
Major events 0.2
Price of Novoseven in Iran’s market* 7750 rials/g
* Based on official exchange rate US $1  12,260 rials.* Based on official exchange rate US $1  12,260 rials.Sensitivity analysis
The sensitivity analysis was performed for important variables
related to this study. Costs calculation for both methods was re-
peated for different values of variables mentioned in Table 3. The
results showed that the breakeven point was sensitive to a num-
ber of variables including cost of medicines, dose, and the success
rate of the treatment protocols. The breakeven point was calcu-
lated as cross point of lines represented for total costs attributed to
ITI and on-demand therapy with bypassing agent regimen (Fig. 1).
Results
Results of a sample cost calculation for ITI and bypassing agent are
summarized in Table 4. This table has been created on the basis of
the assumption of 80% success rate for ITI and current prices of
medicines in the Iranian market. The management of 10 patients
with the ITI method (100 IU/Kg/d of FVIII) in the first year will cost
21,900,000,000 rials. On the other hand, in this year Iran’s MOH will
need to pay 2,301,750,000 rials for the management of bleeding
episodes of these patients using Novoseven. Therefore, the total
costs of the ITI arm of this study will reach 24,201,750,000 rials in
the first year. Based on the success rate of 80% for the ITI method
and therefore need of 20% of patients for Novoseven, the costs of
the management of patients in the second year in this group will
be 4,209,150,000 rials. Cumulative costs of first and second years
will be 28,410,900,000 rials. Costs attributed to this group in the
third year will be 4,591,800,000 rials. However, total costs for the
management of 10 patients using on-demand therapy with No-
voseven will be 15,484,500,000, 17,032,950,000, and 18,581,400,000
for first, second, and third year post treatment, respectively. To
calculate the breakeven point, costs versus time for each arm were
graphed. The breakeven point was defined as the intersection of
these two graphs (Fig. 1).
Based on sensitivity analysis, the breakeven point very much
depends on costs of FVIII, Novoseven, and the success rate of the
ITI intervention. Ranges of variables used for sensitivity analysis
are summarized in Table 3. According to this analysis, the
breakeven point of ITI and Novoseven methods varies between 16
and 34 months post treatment. However, based on current price of
medicines in the Iranian market and the assumption of 80% suc-
cess rate for the ITI method, the breakeven point was calculated at
about 17 months post treatment.
Conclusions
The main objective of this study was to calculate the breakeven
point for the implementation of ITI versus on-demand therapy
with Novoseven in high-responder hemophilia patients with in-
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Fig. 1 – Breakeven analysis for the ITI group and on-
demand therapy with Novoseven. US $1 = 12,260 rials. ITI,
immune tolerance induction.hibitors from Iran’s MOH perspective. Iran’s health system pro-
Table 4 – Samples of costs calculations for the ITI method versus on-demand therapy with Novoseven.
First year FVIII
(IU/kg/d)
Patient
Wt. (kg)
Time
length (d)
Total
FVIII (IU)
Price of
FVIII/IU*
Cost/patient* No. of
patients
Total
costs*/year
100 20 365 730,000 3000 2,190,000,000 10 21,900,000,000
Novoseven
(g/kg/event)
Patient
Wt. (kg)
No. of
events
Price* of
rFVII/g
Total
Novoseven
Cost/patient No. of
patients
Total costs Total costs* (first
year cumulative)
270 20 1.5 7750 8100 62,775,000 10 627,750,000
540 20 1 7750 10,800 83,700,000 10 837,000,000
5400 20 0.1 7750 10,800 83,700,000 10 837,000,000 2,301,750,000
24,201,750,000
Second year FVIII
(IU/kg/d)
Patient
Wt. (kg)
No. of
events
Total
FVIII (IU)
Price of
FVIII/IU*
Cost/patient* No. of
patients
Total costs Total costs* (first
year cumulative)
40 22 27 23,760 3000 71,280,000 8 570,240,000
80 22 3 5280 3000 15,840,000 8 126,720,000
1000 22 0.2 4400 3000 13,200,000 8 105,600,000 802,560,000
Novoseven
(g/kg/event)
Patient
Wt. (kg)
No. of
events
Price* of
rFVII/g
Total
Novoseven
Cost/patient No. of
patients
Total costs
270 22 27 7750 160,380 1,242,945,000 2 2,485,890,000
540 22 3 7750 35,640 276,210,000 2 552,420,000
5400 22 0.2 7750 23,760 184,140,000 2 368,280,000 3,406,590,000
4,209,150,000
28,410,900,000
Third year FVIII (IU/kg/d) Patient
Wt. (kg)
No. of
events
Total
FVIII (IU)
Price of
FVIII/IU*
Cost/patient No. of
patients
Total costs Total costs* (third
year cumulative)
40 24 27 25,920 3000 77,760,000 8 622,080,000
80 24 3 5760 3000 17,280,000 8 138,240,000
1000 24 0.2 4800 3000 14,400,000 8 115,200,000 875,520,000
Novoseven
(g/kg/event)
Patient
Wt. (kg)
No. of
events
Price* of
rFVII/g
Total
Novoseven
Cost/patient No. of
patients
Total costs
270 24 27 7750 174,960 1,355,940,000 2 2,711,880,000
540 24 3 7750 38,880 301,320,000 2 602,640,000
5400 24 0.2 7750 25,920 200,880,000 2 401,760,000 3,716,280,000
4,591,800,000
33,002,700,000
FVIII, factor VIII.
* Unit price; US$112,260 rials.
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fore, Iran’s MOH currently spends considerable resources for the
management of patients with rare coagulating disorders.
Because of numerous reports indicating both clinical efficacy and
cost-effectiveness of ITI for the management of hemophilia patients
with inhibitors against FVIII [16], Iran’s MOH decided to implement
the ITI method for the management of high-responder hemophilia
patients. A recently published report evaluated the cost utility of ITI
versus on-demand therapy with Novoseven in Iranian hemophilia
patients with high-titer inhibitors. The report concluded that low-
dose ITI protocol (50 U/kg/d) is a cost-effective option compared with
on-demand treatment with Novoseven in a 10-year period of time [17].
To finance the ITI intervention, Iran’s MOH was interested in
finding out the breakeven point of this method versus the man-
agement of patients using on-demand therapy with Novoseven.
Results of our calculations show that Iran’s MOH will be able to
recover earlier higher expenditure on ITI, because of high doses of
FVIII in first and second years of post treatment, in less than 2
years. Despite the sensitivity of the breakeven point to some vari-
ables (Table 3), a most realistic scenario for the price of FVIII and
Novoseven in the Iranian market and the assumption of 80% suc-
cess rate for the ITI method (Table 4) show that the breakeven
point for these two methods will be at about 17 months post treat-
ment (Fig. 1). Therefore, Iran’s MOH will recover all costs attrib-
uted to the ITI method in 17 months of starting the ITI program
and will have substantial saving on the management of these pa-
tients in coming years afterward. The money saved could also be
allocated to other priorities of Iran’s health sectors.
However, this study had one important limitation, which is the
exchange rate for Iran’s national currency (rial). As is already men-
tioned, the estimation of the breakeven point is very sensitive to
the price of medicines. Both medicines used for the management
of these patients (FVIII and Novoseven) are imported medicines,
and the exchange rate plays a major role in their final price. Al-
though we used the official exchange rate for rial versus interna-
tional currencies, in recent months, rial has experienced a sub-
stantial devaluation. Rial has lost about 30% of its value in recent
months, and this might affect the final result and the conclusion of
this study. Otherwise, the results of this study clearly show that
the ITI method is a cost-saving method for the management of
high-responder inhibitor hemophilia patients when compared
with on-demand therapy with Novoseven.
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